MedTrace Logo

Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance

NCT01624077 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-02-24

No results posted yet for this study

Summary

The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for graft specific tolerance induction).

Conditions

  • Chronic Rejection of Liver Transplant

Interventions

BIOLOGICAL

Regulatory T cells

Tregs will inject after liver transplantation

Sponsors & Collaborators

Principal Investigators

  • Hong Wang, MD · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624077 on ClinicalTrials.gov